Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 42,322	$ 41,827
In process research and development	20	30
General and administrative	12,001	11,346
Total operating expenses	54,343	53,203
Loss from operations	(54,343)	(53,203)
Other income (expense)
Interest income	224	193
Interest expense	(3,467)	(4,780)
Other income (expense)	(199)	149
Total other income (expense), net	(3,442)	(4,438)
Net loss	(57,785)	(57,641)
Other comprehensive loss:
Foreign currency translation, net of tax	(8)	(372)
Unrealized loss on marketable securities, net of tax	(377)	(69)
Other comprehensive loss	(385)	(441)
Comprehensive loss	$ (58,170)	$ (58,082)
Net loss per share, basic (in dollars per share)	$ (0.76)	$ (0.78)
Net loss per share, diluted (in dollars per share)	$ (0.76)	$ (0.78)
Weighted average common shares outstanding, basic (in shares)	75,894,692	74,093,526
Weighted average common shares outstanding, diluted (in shares)	75,894,692	74,093,526